Efficacy and Safety of the Fixed Dose Combination of Glimepiride+Metformin in Type 2 Diabetic Patients Inadequately Controlled
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 167 participants.
Also called NCT01699932
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 167 participants
- Sponsor
- Registry
-
NCT01699932
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Lebanon, Russia, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT01699932. Non-randomized; no masking; primary purpose treatment. Start 2012-09 (registry gives no type); primary completion 2014-04 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of the Fixed Dose Combination of Glimepiride+Metformin in Type 2 Diabetic Patients Inadequately Controlled
- Acronym
- LEGEND
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Glimepiride+metformin (Amaryl M®) - HOE4900
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct01699932- Content hash
44cc19a427e8f591557d122c47277db225454ed7698e84f8355382595875c14e